Stephen Basso
Finanzdirektor/CFO bei INNOVIVA, INC.
Profil
Stephen Basso's career history includes current and former positions as well as education.
Currently, he is the Chief Financial Officer at Innoviva, Inc. In the past, he held the position of Vice President-North America Commercial at Alexion Pharmaceuticals, Inc. from 2009 to 2017.
From 2017 to 2021, he served as the Chief Financial Officer & Senior VP-Finance at Inozyme Pharma, Inc. Additionally, he has experience as the Chief Operating & Financial Officer at Cybrexa, Inc. Mr. Basso obtained an MBA from Boston College and completed his undergraduate degree at Providence College.
Aktive Positionen von Stephen Basso
| Unternehmen | Position | Beginn |
|---|---|---|
| INNOVIVA, INC. | Finanzdirektor/CFO | 21.08.2023 |
Ehemalige bekannte Positionen von Stephen Basso
| Unternehmen | Position | Ende |
|---|---|---|
| INOZYME PHARMA, INC. | Finanzdirektor/CFO | 14.05.2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2017 |
Cybrexa, Inc.
 Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Finanzdirektor/CFO | - |
Ausbildung von Stephen Basso
| Providence College | Undergraduate Degree |
| Boston College | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| INNOVIVA, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
